Gilead Sciences (NASDAQ:GILD) CEO Sells $2,546,100.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel O’Day sold 15,000 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $169.74, for a total transaction of $2,546,100.00. Following the transaction, the chief executive officer owned 551,683 shares in the company, valued at approximately $93,642,672.42. The trade was a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Patrick O’day also recently made the following trade(s):

• On Friday, October 30th, Daniel O’Day sold 15,881 shares of Gilead Sciences stock. The stock was sold at an average price of $175.25, for a total transaction of $2,783,145.25.
• On Thursday, October 1st, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $147.90, for a total transaction of $2,218,500.00.
• On Tuesday, September 1st, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $148.64, for a total transaction of $2,229,600.00.

Gilead Sciences Price Performance

NASDAQ GILD traded down $0.35 during trading hours on Monday, hitting $170.33. The company’s stock had a trading volume of 8,856,542 shares, compared to its average volume of 5,751,038. Gilead Sciences, Inc. has a twelve month low of $116.88 and a twelve month high of $175.65. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The stock has a fifty day moving average of $151.36 and a 200 day moving average of $140.03.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. The firm had revenue of $8.30 billion during the quarter, compared to analyst estimates of $7.81 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.47 EPS. As a group, equities analysts predict that Gilead Sciences, Inc. will post -1.03 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 1.9%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently -103.80%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on GILD shares. Truist Financial upped their price objective on Gilead Sciences from $158.00 to $181.00 and gave the company a “buy” rating in a report on Friday. Royal Bank Of Canada raised their target price on Gilead Sciences from $126.00 to $131.00 and gave the stock a “sector perform” rating in a report on Friday. Bank of America boosted their target price on Gilead Sciences from $168.00 to $172.00 and gave the stock a “buy” rating in a research report on Tuesday, October 20th. Leerink Partners cut Gilead Sciences from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $146.00 to $127.00 in a research note on Tuesday, July 21st. Finally, Citigroup increased their price target on shares of Gilead Sciences from $165.00 to $188.00 and gave the company a “buy” rating in a research report on Friday. Twenty-three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $169.74.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead said it will present late-breaking clinical data and real-world evidence from more than 50 studies at HIV Glasgow 2026 on November 8–11. Updates on HIV therapies, its development pipeline and strategic collaborations could provide catalysts if the results reinforce the company’s leadership in HIV treatment. Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow
• Positive Sentiment: Analysts have raised several Gilead price targets, including targets of $175, $181, $183, $188, $190 and $200. Separately, an updated fair-value estimate rose from $158.65 to $165.31, reflecting improved views of third-quarter execution, the HIV business and pipeline assets. Gilead Sciences Price Target Raised to $200.00 Gilead Stock Fair Value Edges Higher After Analyst Target Increases
• Positive Sentiment: Gilead continues to receive favorable analyst attention, including a Morgan Stanley Buy rating and inclusion among healthcare stocks described as having Strong Buy ratings and high quantitative scores. Gilead Sciences Receives a Buy from Morgan Stanley
• Neutral Sentiment: Former Gilead U.S. Medical Affairs head Dean Hakanson joined GOA Therapeutics as chief medical officer. The move highlights executive experience gained at Gilead, but it does not directly change Gilead’s operations or financial outlook. Former Gilead Head of U.S. Medical Affairs Joins GOA Therapeutics
• Negative Sentiment: One recent earnings analysis characterized Gilead’s outlook as mixed: revenue guidance was raised, but the EPS outlook worsened. That contrast could limit upside by raising concerns about profitability even as the HIV business remains strong. Gilead Sciences Q3 2026 Earnings Analysis

Hedge Funds Weigh In On Gilead Sciences

Several institutional investors have recently modified their holdings of GILD. BlackRock Inc. acquired a new stake in shares of Gilead Sciences during the second quarter worth $15,393,785,000. State Street Corp lifted its position in Gilead Sciences by 2.3% in the 2nd quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock valued at $7,734,099,000 after acquiring an additional 1,357,967 shares in the last quarter. Amundi lifted its position in Gilead Sciences by 10.7% in the 1st quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock valued at $1,468,836,000 after acquiring an additional 1,018,976 shares in the last quarter. Legal & General Group Plc bought a new stake in Gilead Sciences in the 2nd quarter valued at $1,316,606,000. Finally, Deutsche Bank AG acquired a new position in Gilead Sciences in the 2nd quarter worth $918,387,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.